Hemab Therapeutics (NASDAQ:COAG) Reaches New 52-Week High – Time to Buy?

Shares of Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) reached a new 52-week high on Monday . The stock traded as high as $37.70 and last traded at $37.13, with a volume of 70017 shares traded. The stock had previously closed at $32.37.

Wall Street Analysts Forecast Growth

COAG has been the topic of a number of recent research reports. Zacks Research raised Hemab Therapeutics to a “hold” rating in a research report on Wednesday, May 27th. Wall Street Zen raised Hemab Therapeutics to a “hold” rating in a research report on Saturday, May 9th. Jefferies Financial Group initiated coverage on shares of Hemab Therapeutics in a research note on Tuesday, May 26th. They set a “buy” rating and a $39.00 price target for the company. Wedbush began coverage on shares of Hemab Therapeutics in a research report on Tuesday, May 26th. They issued an “outperform” rating and a $42.00 price objective on the stock. Finally, Evercore assumed coverage on shares of Hemab Therapeutics in a report on Tuesday, May 26th. They set an “outperform” rating and a $50.00 target price for the company. Five research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $41.40.

Hemab Therapeutics Trading Up 16.1%

Hemab Therapeutics (NASDAQ:COAG) last released its quarterly earnings data on Thursday, May 21st. The company reported ($23.98) EPS for the quarter.

Insider Transactions at Hemab Therapeutics

In other news, major shareholder Ra Capital Management, L.P. acquired 61,523 shares of the firm’s stock in a transaction on Tuesday, June 16th. The shares were purchased at an average cost of $24.98 per share, with a total value of $1,536,844.54. Following the acquisition, the insider directly owned 6,444,637 shares in the company, valued at $160,987,032.26. This represents a 0.96% increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. In the last ninety days, insiders acquired 2,970,541 shares of company stock valued at $55,459,603.

About Hemab Therapeutics

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.